Cipla Ltd · NSE:CIPLA
Cipla — Q2 FY27 Earnings Presentation
17 slides from Cipla's earnings presentation, Oct 27, 2026
Slide 1: Exchange filing cover letter for Q2FY27 investor presentation
27th October, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 S
Slide 2: Investor Presentation Q2FY27
Investor Presentation Q2FY27 27-10-2026 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual
Slide 4: Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum
Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum Revenue EBITDA PAT Q2FY27 INR 7,404 Cr INR 1,388 Cr 18.7% INR 878 Cr 11.9% Margin Margin Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 3,516 Cr 12% $ 172 Mn $ 12
Slide 5: Financial Performance: Q2FY27
Financial Performance : Q2FY27 Revenues INR 7,404 Cr EBITDA 1,388 Cr Revenue1 Break-up Q2FY27 (Consolidated) API and Q2FY27 Q2FY26 Others, 1% (INR Cr) (INR Cr) Emerging markets and Total Revenue from 7,404 7,589 Europe, 13% Operations EBITDA 1,388 1,895 One Africa, EBITDA % 18.7% 25.0% 16% One India
Slide 6: One India: Building a Sustainable Legacy for Enduring Growth
One India1 : Building a Sustainable Legacy for Enduring Growth Highest-ever quarterly revenue of INR 3,516 Cr Branded Prescription Trade Generics Consumer Health ❖ Cipla maintained #2 rank in overall chronic segment2 ❖ Delivered a strong double-digit ❖ Anchor and transitioned brands ❖ Continued port
Slide 7: India Rx: Strengthening Our Journey with Strategic Therapeutic Focus
India Rx : Strengthening Our Journey with Strategic Therapeutic Focus Steady Uptake in Key Therapies1 Growth (%) Rank Largest pharma company by volume (units) 1st in market2 Respiratory 11% Urology 11% 2nd Our in-house brand franchise, Dytor2, has scaled to over INR 800 Cr+ Anti-diabetic 50% 8th Car
Slide 8: Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies
Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies Respiratory Diabetology Cardiology Critical Care India’s first once-daily Galvus DM [ Vildagliptin SR+ Dytor E FDC Rizontem (Aztreonam and nebulized bronchodilator for Dapagliflozin+ Metformin SR] is [Torsemide+Eplerenone] i
Slide 9: Strategic Alliances during the Quarter
Strategic Alliances during the Quarter Bispecific HER2 ADC Pembrolizumab Biosimilar ❑ Exclusive licensing agreement with CTTQ ❑ Exclusive U.S. licensing and supply partnership (SinoBiopharma Group) for TQB2102 across with Qilu Pharmaceutical for QL2107, a India, South Africa and five other emerging
Slide 10: Q2 FY27: Global Consumer Wellness Franchise
Q2 FY27 : Global Consumer Wellness Franchise One India One Africa Consumer Brands in One India Revenue : INR 427 Cr Smoking Pain Pain Relief Respi OTC Cessation Management Consumer Brands in Respi OTC Cold and Flu Hydration Skin Infection South Africa Revenue : ZAR 463 Mn Cold and Cold and Cough Cou
Slide 11: North America: Adapting to Evolving Business Dynamics
North America : Adapting to Evolving Business Dynamics Key Business Highlights – Q2FY27 ▪ gProventil ranked No. 1 with total market1 share at 22% (50 million+ inhaler units supplied to the U.S. market cumulatively) ▪ Received U.S. FDA approval for gAdvair Diskus across all three strengths (100/50, 2
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 30th September 2026)
ANDA & NDA Portfolio & Pipeline (As on 30th September 2026) 7 69 9 106 2 2 4 3 23 37 19 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 191 44 46 281 Approved Tentatively Under Approval Total ANDAs & NDAs Approved AN
Slide 13: One Africa: South Africa Private Growing Faster than the Market
One Africa1 : South Africa Private Growing Faster than the Market SA Key Highlights2 21 11 21 ▪ Healthy performance across key therapies like G.U. 23 10 system + Sex Hormones, Nervous System and 12 Dermalogicals 80 80 ▪ 10 brands with MAT market revenue > 100 Mn ZAR ▪ Highest number of brands in top
Slide 14: Progress on ESG goals (India Manufacturing Operations): Q2FY27
Progress on ESG goals (India Manufacturing Operations) : Q2FY27 Aspects Goals FY 2029-30 Progress Renewable Electricity Share 80% renewable electricity share for India manufacturing 77%* • 30% absolute reduction (Scope 1-Energy based & 44%** GHG Emissions Scope-2) from baseline of FY2023-24 for Glob
Slide 15: Consolidated Profit and Loss Statement Summary
Consolidated Profit and Loss Statement Summary INR Cr Particulars Q2FY27 Q2FY26 Revenue from sale of products 7,368 7,447 Other operating income 36 142 Income from operations 7,404 7,589 Material cost 2,634 2,498 Employee benefits expense 1,475 1,315 Other expenses 1,908 1,882 Total expenses 6,016 5
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet INR Cr Key Balance Sheet Items Sep-26 Sep-25 Equity 35,522 33,025 Total Debt# 699 467 Inventory 6,778 6,160 Cash and Cash Equivalents* 10,522 10,368 Trade Receivables 6,000 6,902 Trade Payables 3,266 3,035 Net Tangible Assets 8,266 6,996 Goodwill and Intangibles 7,107 5,37
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 Diksha Maheshwari Investor.Relations@cipla.com For more information, please visit www.cipla.com 16